On October 2, 2018 IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise") (TSX Venture: IPA, Pink Sheets: IPATF) reported its financial results for Q1 ended July 31, 2018 (Press release, ModiQuest Therapeutics, OCT 2, 2018, View Source [SID1234530114]). The financial statements and related management’s discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial Highlights:

Revenue.During the three months ended July 31, 2018, the Company increased revenues to $2,872,785 from $591,058 in 2017. This represents a 386% increase in revenue, in part, from the acquisitions of U-Protein Express and ModiQuest Research, the Company’s ability to grow its capacity in its core business and expand its market share in Europe, as well as growth in higher revenue services.
Gross Margin. During the three months ended July 31, 2018, the Company increased its gross margin to $1,567,826 from $46,658 in 2017. In percentage terms, the Company’s gross margin increased to 55% from 8% in 2017. The lower gross margin in 2017 was mostly attributable to the fact that the Company increased its staffing levels, made salary adjustments and incurred higher lab operating costs to accommodate greater levels of activity in 2017, which drove down the gross margin.
Net Loss. The Company recorded a net loss of $1,102,362 during the three months ended July 31, 2018, compared to net loss of $857,832 for three months ended July 31, 2017. The net loss increased in 2018, primarily as a result of the acquisitions of U-Protein and ModiQuest, which required higher expenses in all facets of the business in order to manage a global landscape. The Company continues to invest in research and development as it broadens the breadth and value of its intellectual property assets.
Growth Initiatives in Fiscal 2018:

European Acquisitions. ImmunoPrecise acquired two profitable companies within the EU during the Fiscal year of 2018, U-Protein Express (August, 2017) and ModiQuest Research (April, 2018). These acquisitions will enhance ImmunoPrecise’s position as a leading, full-service antibody CRO, by strengthening its ability to partner with clients across the entire antibody discovery, manufacturing, and engineering continuum.These acquisitions also enhance ImmunoPrecise’s ability to achieve its longer-term goals by scaling to meet demand, and by expanding our global biotechnology and pharmaceutical client base.
Full-Service B-Cell Facility. During the Fiscal year of 2018, ImmunoPrecise expanded its B-cell offerings in both North America and Europe. This expansion will enable the ImmunoPrecise family of companies to increase its capacity for B-cell services supporting therapeutic antibody development, provide a client-centric focus with worldwide production centers, and help to bring leading antibody discovery services to more pharmaceutical and biotech companies around the world.
"We believe our strong revenue growth reflects our progress toward the goal of aligning our Companies’ unique continuum of services, supporting clients from target selection through pre-clinical studies, with an ever-strong and growing, global market. There has been an impressive increase in the scale of services requested by prospects and clients, further confirming the value of investing in our global presence to emerge as a leader in the full-service, antibody discovery and development sector," stated CEO and President, Dr. Jennifer Bath. "We are happy with our second-quarter performance, the integration of our new production sites, and we are optimistic about continued growth in revenue and shareholder value."

On October 2, 2018 Nordic Nanovector ASA (OSE: NANO) reported that an abstract reporting data from the Phase 1/2a LYMRIT 37-01 study investigating Betalutin (177Lu-lilotomab satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma (iNHL) has been accepted for a poster presentation at the 60th Annual Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition (1-4 December 2018, San Diego, CA) (Press release, Nordic Nanovector, OCT 2, 2018, View Source [SID1234553494]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: LYMRIT 37-01: A phase I/II study of 177Lu-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-Hodgkin’s lymphoma (NHL) – Analysis with 6-month follow-up

Authors: A. Kolstad, et al.

The Company will also have two non-clinical posters: one presenting Betalutin and one presenting the investigational anti-CD37 radioimmunoconjugate 212Pb-NNV003, which is under evaluation in a research collaboration between Nordic Nanovector and Orano Med (formerly AREVA Med).

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177Lu-lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma

Authors: G.R. Rødland et al.

Targeted Alpha Therapy with 212Pb-NNV-003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Authors: A. Saidi et al.

The abstracts will be published on 1 November 2018 at 09:00am Eastern time at View Source

On October 2, 2018 Medigene AG (FSE: MDG1, Prime Standard, SDAX) reported its participation at the following upcoming investor and scientific conferences (Press release, MediGene, OCT 2, 2018, View Source [SID1234529709]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper)
Date: 30 September – 03 October 2018
Location: New York, USA

European Society of Gene and Cell Therapy (ESGCT) Annual Congress
Date: 16 – 19 October 2018
Location: Lausanne, Switzerland

ESMO – European Society for Medical Oncology Congress
Date: 19 – 23 October 2018
Location: Munich, Germany

BTIG Healthcare Conference
Date: 25 October 2018
Location: New York, USA

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

On October 2, 2018 PharmAbcine, Inc, a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications reported that the company received "Study May Proceed Letter " from the US Food and Drug Administration (FDA) for the Investigational New Drug ("IND") application of its flagship antibody, TTAC-0001 (Press release, PharmAbcine, OCT 2, 2018, View Source [SID1234529710]). This enables the Company to begin opening US clinical trial sites for phase II clinical trial with bevacizumab (Avastin) refractory recurrent GBM patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recurrence of GBM is inevitable and recurrent GBM (rGBM) is one of the most aggressive and has the worst prognosis. The treatment options are limited with modest activity for rGBM. Therefore, there is no universally held standard of care available till now.

Patients with rGBM are suffering under cerebral edema and partially responded to bevacizumab. However, patients responded to bevacizumab ultimately become non-responder during the treatment and once patients become bevacizumab non-responder, unfortunately, there are no more therapeutic options.

Cerebral edema comes from excessive secretion of VEGF-A, B, C and D from brain tumors. While bevacizumab traps VEGF-A only, TTAC-0001 binds to VEGFR2 specifically and interferes the activation of VEGFR2 by VEGF-A, C and D.

TTAC-0001 has completed its phase IIa in recurrent GBM in Australia last year with clear safety profile (all DAE maintain within grade 2) and 25% disease control rate. rGBM patients in the study responded to TTAC-0001 for cerebral edema (>40%). No hypertension, hemorrhage, gastric/lung perforation or proteinuria have been observed.

Jin-San Yoo, CEO of PharmAbcine, Inc., commented: "As part of the study design, it was always planned that US trial sites would become part of our Bevacizumab refractory recurrent GBM Phase II clinical trial. We are pleased with today’s IND approval from the FDA as it will accelerate patient enrolment into the global bevacizumab recurrent GBM phase II trial. Moreover, the FDA’s decision is positive news for eligible American sufferers under this devastating condition who can now participate in the study."

This research was supported by Korea Drug Development Fund (KDDF) funded by MSIT, MOTIE and MOHW (Grant No. KDDF201509-07, Republic of Korea)

On October 2, 2018 Quentis Therapeutics, Inc., a biotechnology company developing therapies that target endoplasmic reticulum (ER) stress pathways, reported that FierceBiotech has named the company to its "Fierce15" list for 2018, designating Quentis as one of the most promising private emerging biotechnology companies (Press release, Quentis Therapeutics, OCT 2, 2018, View Source [SID1234529833]). Quentis also announced the appointment of industry veteran, Mark Murcko, PhD, to its Board of Directors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Quentis is thrilled to be recognized by FierceBiotech at this stage in the company’s growth and development. The science and understanding of the role of ER stress in disease has advanced significantly, providing a path to develop new therapies with the potential to treat cancer and other diseases in a meaningful way. Our lead program has the potential to overcome suppression and restore normal immune-cell function in the tumor micro-environment leading to increased tumor killing and improved patient outcome," said Michael Aberman, MD, President and CEO of Quentis Therapeutics.

The endoplasmic reticulum (ER) is a structure within cells that is responsible for multiple functions, including serving as a sensor of cellular stress. Many diseases, including cancer, neurodegenerative, and autoimmune diseases, can cause persistent ER stress, triggering aberrant responses that disrupt normal cellular functions. The company’s lead program is a first-in-class IRE1α inhibitor designed to boost anti-tumor immunity in cancer. Quentis plans to advance a pipeline of programs designed to address ER stress in multiple diseases.

Sponsored by FierceBiotech, an internally recognized provider of life science news and analysis, Fierce15 is an annual award bestowed upon 15 privately held-life science companies that embody the word "fierce" – championing innovation and creativity in the face of intense competition. Now in its 16th year, recipients are selected from hundreds of private companies from around the world based on the strength of their technology and science, partnerships, investors and competitive market position.

New Appointment to Board of Directors

Quentis also announced that Dr. Murcko has joined its Board of Directors providing deep experience in drug discovery and development. Dr. Murcko is a Founder, Board member, and served as interim chief scientific officer of Relay Therapeutics. He is a senior lecturer in the Department of Biological Engineering at MIT and has served on scientific advisory boards and corporate boards of directors for a diverse range of organizations. Prior to co-founding Relay Therapeutics, Dr. Murcko was chief technology officer and chair of the Scientific Advisory Board of Vertex Pharmaceuticals. He previously worked at Merck Sharpe & Dohme, where he helped discover multiple drug candidates. Dr. Murcko has directly contributed to the development of seven marketed drugs over his career, is a co-inventor on more than 50 issued and pending patents, and has co-authored more than 85 scientific articles. He holds a PhD in organic chemistry from Yale University.

"I am excited to join the Board of Directors at this important time and look forward to collaborating with the talented Quentis team to realize the promise of ER stress in cancer and beyond," said Dr. Murcko